Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, February 2000, p. 344-347, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Mechanisms of Artemisinin Resistance in the Rodent
Malaria Pathogen Plasmodium yoelii
Daniel J.
Walker,1
Jessica L.
Pitsch,1
Michael M.
Peng,1
Brian L.
Robinson,2
Wallace
Peters,2
Jamaree
Bhisutthibhan,1 and
Steven R.
Meshnick1,*
Department of Epidemiology, University of Michigan School
of Public Health, Ann Arbor, Michigan 48109,1
and Tropical Parasitic Diseases Unit, Northwick Park
Institute for Medical Research, Harrow, Middlesex HA1 3UJ, United
Kingdom2
Received 8 February 1999/Returned for modification 28 May
1999/Accepted 23 November 1999
 |
ABSTRACT |
Artemisinin and its derivatives are important new antimalarials
which are now used widely in Southeast Asia. Clinically relevant artemisinin resistance has not yet been reported but is likely to
occur. In order to understand how the malaria parasite might become
resistant to this drug, we studied artemisinin resistance in the murine
malaria parasite Plasmodium yoelii. The
artemisinin-resistant strain (ART), which is approximately fourfold
less sensitive to artemisinin than the sensitive NS strain, accumulated
43% less radiolabeled drug in vitro (P < 0.01).
Within the parasite, the drug appeared to react with the same parasite
proteins in both strains. The translationally controlled tumor protein,
one of the artemisinin target proteins, did not differ between the
strains. No DNA sequence difference was found, but the resistant strain was found to express 2.5-fold-more protein than the sensitive strain
(P < 0.01). Thus, the phenotype of artemisinin
resistance in P. yoelii appears to be multifactorial.
 |
INTRODUCTION |
Drug-resistant malaria is a major
worldwide public health problem. In Southeast Asia, for example,
Plasmodium falciparum strains have become resistant to all
of the classical antimalarials (12). Fortunately, these
strains are still susceptible to the artemisinin derivatives;
derivatives such as artemether and artesunate are now widely used in
this region (11).
Artemisinin was originally isolated from Artemisia annua, an
herb used as an ancient Chinese herbal remedy. All of the artemisinin compounds contain stable endoperoxide bridges. Evidence from a variety
of labs suggests that the antimalarial activity of artemisinin is
dependent on the cleavage of the endoperoxide by intraparasitic heme.
The cleaved endoperoxide ultimately becomes a carbon-centered free
radical which then functions as an alkylating agent, reacting with both
heme and parasite proteins (but not DNA) (7, 11, 14). In
P. falciparum, one of the principal alkylation targets is
the translationally controlled tumor protein (TCTP) homolog (4). Some intraparasitic TCTP is situated in the membrane
surrounding the heme-rich food vacuole (5), where heme could
catalyze the formation of drug-protein adducts.
Clinically relevant resistance to artemisinin derivatives has not yet
been reported, although P. falciparum isolates may vary two-
to fourfold in their in vitro sensitivities to these drugs (2, 3,
18). However, since the drugs are being widely used, artemisinin
resistance is likely to develop in the near future. Recently, a strain
of the murine malaria parasite Plasmodium yoelii with
unstable resistance to artemisinin was obtained (13). Here
we attempted to characterize the mechanisms of resistance in this strain.
 |
MATERIALS AND METHODS |
Parasites.
Plasmodium yoelii strains ART and NS
(13) were passaged and grown in male ICR mice (Harlan,
Indianapolis, Ind.) by intraperitoneal injection of 106
parasitized erythrocytes. Each mouse infected with the resistant strain
was given a subcutaneous injection of artemisinin (150 mg/kg of body
weight in sesame oil). When parasitemias were >20%, mice were
anesthetized with ketamine and exsanguinated by cardiac puncture with a
heparinized syringe. The blood was diluted with RPMI 1640 (Gibco BRL,
Gaithersburg, Md.) and washed twice. All reagents were obtained from
Sigma Chemical Co. (St. Louis, Mo.) unless otherwise noted.
Uptake of radiolabeled drug and reaction with parasite
proteins.
Freshly obtained infected erythrocytes were suspended
into RPMI 1640 to a hematocrit of 10%. Each incubation used infected cells from a single mouse; infected erythrocytes from four ART- and six
NS-infected mice were used. To each suspension, 0.65 µCi of
[10-3H]dihydroartemisinin (1.8 Ci/mmol; Moravek
Biochemical, Brea, Calif.) ([3H]DHA) was added per ml.
The mixture was incubated in a 37°C water bath for 3 h. After
the cells were washed twice with RPMI 1640, the parasites were isolated
by saponin lysis (8) and stored at
80°C. After thawing,
5 to 10 µl was removed and added to 30 µl of 10 mM Tris-HCl (pH
7.2). The samples were then sonicated for 5 s followed by
centrifugation at 20,000 × g for 5 s at room temperature. The pellets were discarded. Protein concentrations in the
supernatants were determined with the Bio-Rad microassay (6). In some experiments, the pellets were first solubilized in 1% sodium dodecyl sulfate (SDS) at 4°C for 15 min followed by
centrifugation for 30 min at 14,000 × g. To measure
radioactivity, aliquots of parasite homogenate (5 µl) were added to 5 ml of scintillation fluid (ScintiVerse BD). Counts were measured in a
Beckman LS7000 scintillation counter. To identify radiolabeled protein
bands, the same parasite homogenates (20 µg) were run on 10% NuPAGE
gels (Novex, San Diego, Calif.) at 200 V for 30 min. After staining of
the gels with Coomassie blue, the gels were treated with
En3Hance (NEN Life Science Products, Boston, Mass.), dried,
and exposed to X-Omat XAR2 autoradiography film (Eastman Kodak Co.,
Rochester, N.Y.) for 60 days at
80°C. Prints of the autoradiograms
were made on electrophoresis duplicating paper (Eastman Kodak Co.).
DNA amplification and sequencing.
Erythrocytes were pelleted
and washed three times with phosphate-buffered saline (PBS) and
disrupted with lysis buffer (10 mM Tris-HCl [pH 7.5], 10 mM EDTA, 1%
SDS) at 60°C for 15 min. The lysed sample was treated with RNase
(Boehringer Mannheim, Indianapolis, Ind.) (final concentration, 50 µg/ml) at 37°C for 1 h. Following RNase treatment, the sample
was incubated overnight at 37°C with proteinase K. Protein was
removed by two extractions with phenol-chloroform-isoamyl alcohol
(25:24:1). DNA was precipitated with sodium acetate (final
concentration, 0.3 M), washed in 70% ethanol, and reprecipitated in TE
buffer (10 mM Tris-HCl, 1 mM EDTA [pH 8.0]).
PCR.
Primers selected for this study were based on the
P. falciparum TCTP sequence. Two pairs of 5'- and 3'-end
primers (both pairs added in a 1:1 ratio) were used in the
amplification procedure because of variability in the codons' third
position. The two 5' primers were PyA1
(5'-ATGAAAGTATTTAAAGATGTATTTAC) and PYA2 (5'-ATGAAAGTTTTCAAAGACGTTTTCAC), and the two 3' primers were
PyB1 (5'-TTTTTCTTCAAATAATCCATC) and PyB2
(5'-TTTTTCTTCGAAAAGACCGTC). These primers were also used for
sequencing the fragments. Primer synthesis and DNA sequencing were done
at the Biomedical Research Core Facilities on the University of
Michigan campus. In a total volume of 100 µl, 10 µl of a 10× PCR
buffer (500 mM KCl, 100 mM Tris-HCl [pH 8.3]) was combined with 2 mM
MgCl2, 2.5 U of Ampli-Taq (Perkin-Elmer, Foster City,
Calif.), 200 µM deoxynucleoside triphosphates (Boehringer Mannheim),
a 0.25 µM concentration of each primer, and 5 µg of DNA template.
Amplification of DNA for the PCR was done in a PTC-100 (MJ Research,
Watertown, Mass.). A 48 to 38°C touchdown program was used; this
program begins with a 3-min hot start at 94°C followed by the first
cycle, which includes a 92°C denaturation step for 30 s, a
48°C annealing step for 1 min, and a 72°C extension step for 1 min.
This is repeated for 10 cycles except that the annealing temperature
decreases 1°C each cycle. There are an additional 20 cycles using
38°C as the annealing temperature. An 8-min extension at 72°C
follows the last cycle. The reaction products were purified on a 1%
low-melting-point agarose gel (Gibco BRL) and extracted using a gel
extraction kit (QIAquick; Qiagen, Chatsworth, Calif.). Sequence
alignments were performed on MacVector version 5.0 (International
Biotechnologies, New Haven, Conn.).
Immunoblotting.
Western blots were run for both resistant
and sensitive strains to compare and quantify the pattern and intensity
of the parasite TCTP reaction with antibody made against recombinant
P. falciparum TCTP (6). Parasites were isolated
from the freshly exsanguinated blood by saponin lysis (6)
and stored at
80°C. For each experiment, samples were thawed,
suspended in 10 mM Tris-HCl (pH 7.0), and gently sonicated for 10 s with a Branson sonifier. Electrophoresis was performed on 10% NuPAGE
gels to determine if protein band intensity or pattern differed between
the resistant and sensitive strains. Parasite protein (5 µg) was
loaded into each well and 20 µl of prestained molecular weight
standards (Seeblue; Novex) was added to a single lane. The gel was run
at 200 V for 30 min and placed into a 0.025% Coomassie R-250 stain for
at least 2 h followed by destaining until the background was
clear. Protein was transferred to either nitrocellulose or
polyvinylidene difluoride at 25 V for 1 h using the Novex transfer
system. The membranes were blocked overnight at 4°C in 3% nonfat dry
milk in Tris-buffered saline (20 mM Tris-HCl [pH 7.6], 137 mM NaCl)
with 0.1% Tween 20 followed by a washing in the same buffer. The
membranes were then incubated in anti-TCTP at a concentration of
1:15,000 for 60 min at room temperature. Following extensive washing in
the buffer, the membranes were used in one of two Western blotting protocols. The nitrocellulose membranes were incubated with horseradish peroxidase-conjugated rabbit anti-goat antibody (Dako Corp.,
Carpinteria, Calif.) at a concentration of 1:1,500 for 1 h at room
temperature. Following extensive washing with the buffer, the membranes
were developed by the enhanced chemiluminescence technique (Amersham Pharmacia Biotech) and exposed to autoradiography film. The
polyvinylidene difluoride membranes were incubated with alkaline
phosphatase-linked anti-rabbit antibody at a concentration of 1:10,000
for 1 h at room temperature. Following a washing, these membranes
were developed by the enhanced chemifluorescence (ECF) technique
(Amersham Pharmacia Biotech). The membrane was scanned with the blue
filter using the Molecular Dynamics (Sunnyvale, Calif.) Storm
FluorImager system. The bands from the ECF were quantified to determine
if there was a difference in the density of the reaction between the
resistant and sensitive strains.
To determine the isoelectric point of the TCTP homolog, 25 µg of
parasite protein was placed into the well of an isoelectric focusing
(IEF) gel and run by following the manufacturer's specifications (Novex). Twenty microliters each of IEF standards (Bio-Rad, Hercules, Calif.) was also run on the gel. The protein was transferred to nitrocellulose and immunoblotted as described above except that the
primary antibody was used at a 1:10,000 dilution. The standards were
stained, after the blot was developed, with 0.025% Coomassie R-250.
Statistics.
Standard deviations and significance (as
determined by the Student t test) were calculated using
Microsoft Excel (Macintosh version 5.0).
Nucleotide sequence accession number.
The sequence of the
P. yoelii gene has been given GenBank accession number
AF124820.
 |
RESULTS |
Artemisinin-resistant P. yoelii accumulated
significantly less drug than artemisinin-sensitive parasites
(P < 0.01). Resistant parasites accumulated 43% less
[3H]DHA than sensitive parasites (54.3 versus 94.3 nmol/mg of protein [Table 1]).
Preparations of ART and NS parasites were harvested at approximately
the same day of infection and at approximately the same levels of
parasitemia. The preparations showed no significant difference in stage
distribution (percent trophozoites). The [3H]DHA in both
strains was not membrane associated, since treatment of the lysates
with SDS did not increase measurable counts (data not shown).
We next tested whether [3H]DHA might react with proteins
differently in the two strains. Extracts were made from resistant and
sensitive parasites exposed to [3H]DHA, analyzed by SDS
gel electrophoresis, and exposed to film. Bands were seen at 14, 22.5, 36.5, 42, and >150 kDa in both strains (Fig.
1). The autoradiograms resemble those
previously reported for [3H]DHA-treated P. falciparum (with bands at 25, 32, 42, 50, 65, and >200 kDa)
(1). Bands of similar molecular masses are labeled in each
of the four lanes, but no consistent differences in band intensities
were seen between the two strains.

View larger version (122K):
[in this window]
[in a new window]
|
FIG. 1.
SDS gel autoradiogram of [3H]DHA-treated
P. yoelii ART (artemisinin resistant [R]) and NS
(artemisinin sensitive [S]).
|
|
We then tested whether artemisinin resistance might be associated with
a change in the P. yoelii TCTP sequence or expression levels. The P. yoelii gene was amplified by PCR using
primers based on the P. falciparum gene and sequenced. The
P. yoelii and P. falciparum TCTPs were
identical in 88% of the amino acids and similar in 97% (Fig.
2). The TCTP nucleotide sequence was
identical in both the ART and NS strains.
We then studied the P. yoelii TCTP using antisera prepared
against recombinant P. falciparum TCTP. The molecular mass
of P. yoelii TCTP, as estimated from the immunoblots, was 22 kDa (Fig. 3A). The pI for TCTP was
estimated to be about 4.8 (Fig. 3B). These numbers are similar to those
found for the P. falciparum protein.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Immunoblotting of P. yoelii gels using
anti-TCTP. SDS (A) and IEF (B) gels were run on homogenates of P. yoelii strain NS, immunoblotted with anti-TCTP antibody, and
visualized by enhanced chemiluminescence.
|
|
Artemisinin-resistant parasites contained significantly more TCTP than
sensitive parasites. Resistant and sensitive isolates were analyzed by
SDS gel electrophoresis, transferred to membranes, and immunoblotted
with anti-TCTP. As can be seen in Table
2, there were no significant differences
between the preparations in terms of stage (percent trophozoites) or in
terms of parasitemia and day of sacrifice of the host mouse. The
intensities of the TCTP bands were quantitated with the fluorimager.
The mean densities for the resistant and sensitive strains as
calculated using the ECF protocol differed 2.5-fold (3,344 and 1,375, respectively [Table 2]). This difference was significant at a
P value of <0.01.
 |
DISCUSSION |
This study was a first attempt to understand the mechanisms by
which malaria parasites become resistant to artemisinin and its
derivatives using artemisinin-resistant and -sensitive strains of
P. yoelii. We tested the hypotheses that artemisinin
resistance might be associated with either (i) decreased drug
accumulation or (ii) an alteration in TCTP, a possible drug target.
Resistant parasites were found to accumulate significantly less drug
than sensitive parasites. TCTP had the same sequence in both strains. However, the resistant strain expressed about 2.5 times as much TCTP as
the sensitive strain. Thus, artemisinin resistance in P. yoelii appears to be multifactorial.
Attempts to select for artemisinin-resistant strains of the human
malaria parasite P. falciparum were unsuccessful both in our
lab (unpublished results) and in others (Dennis Kyle, personal communication). Clinical artemisinin-resistant isolates are also not available. Accordingly, we chose to study artemisinin resistance in
the P. yoelii ART strain. There were two drawbacks, however, to working with this model (13). First, the strain exhibits a variable degree of resistance, ranging from 4- to 27-fold. (At the
time of the study, the ART strain was 4-fold more resistant than the NS
strain [unpublished results].) Second, its resistance phenotype is
unstable. It must be passaged in mice administered artemisinin at the
time of passage or else it reverts to a sensitive phenotype.
Fortunately, this latter dose of drug is unlikely to have affected the
parasites used in this study. The half-life of artemisinin is <12 h
(11), and infected erythrocytes were harvested from mice 7 to 8 days after inoculation, so the parasites would have undergone >7
full replication cycles between the time of drug exposure and harvesting.
We previously suggested that TCTP might be a drug target for
artemisinin because P. falciparum TCTP reacts with
[3H]DHA both in vitro and in intact infected
erythrocytes (4). The overexpression of TCTP in
artemisinin-resistant parasites is consistent with this hypothesis.
Overexpression of other drug targets, such as dihydrofolate reductase
and ornithine decarboxylase, has been shown to be associated with drug
resistance in other parasites, such as Leishmania
(16). However, the difference in TCTP expression observed
here might be a secondary effect unrelated to the mechanism of
resistance. Proof of the involvement of TCTP in the mechanism of action
of artemisinin will require either (i) construction of TCTP-deficient
malaria strains or (ii) demonstration that artemisinin treatment
affects TCTP function. Unfortunately, the function of TCTP is currently
unknown, although several functions have been suggested (9, 10,
15, 17).
TCTP of P. yoelii is very similar to that of P. falciparum. The molecular masses are similar (22 for P. yoelii versus 25 kDa for P. falciparum), as are the pIs
(4.8 for P. yoelii versus 4.8 to 4.9 for P. falciparum). A total of 88% of the amino acids were identical,
and the P. yoelii protein reacts well with antibody prepared
against recombinant P. falciparum TCTP. Thus, studies on the
function of P. yoelii TCTP should shed light on the function of TCTP in human malaria parasites.
The artemisinin derivatives are very important new antimalarials that
are now being used widely. It is only a matter of time before
clinically important artemisinin resistance is observed. The results of
this study should offer clues to the mechanism of artemisinin
resistance in human parasites once it arises.
 |
ACKNOWLEDGMENTS |
This work was supported by National Institutes of Health grant
AI-26848 (to S.R.M.).
We thank Paul Hossler, Rosemary Rochford, and Xing-Qing Pan for their help.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department
of Epidemiology, School of Public Health I, University of Michigan, Ann Arbor, MI 48109. Phone: (734) 647-2406. Fax: (734) 764-3192. E-mail: meshnick{at}umich.edu.
 |
REFERENCES |
| 1.
|
Asawamahasakda, W.,
I. Ittarat,
Y. M. Pu,
H. Ziffer, and S. R. Meshnick.
1994.
Reaction of antimalarial endoperoxides with specific parasite proteins.
Antimicrob. Agents Chemother.
38:1854-1858[Abstract/Free Full Text].
|
| 2.
|
Basco, L. K., and J. Le Bras.
1993.
In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum.
Am. J. Trop. Med. Hyg.
49:301-307.
|
| 3.
|
Basco, L. K., and J. Le Bras.
1994.
In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives.
Ann. Trop. Med. Parasitol.
88:137-144[Medline].
|
| 4.
|
Bhisutthibhan, J.,
X. Q. Pan,
P. A. Hossler,
D. J. Walker,
C. A. Yowell,
J. Carlton,
J. B. Dame, and S. R. Meshnick.
1998.
The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin.
J. Biol. Chem.
273:16192-16198[Abstract/Free Full Text].
|
| 5.
|
Bhisutthibhan, J.,
M. A. Philbert,
M. Fujioka,
M. Aikawa, and S. R. Meshnick.
1999.
The Plasmodium falciparum translationally controlled tumor protein: subcellular localization and calcium binding.
Eur. J. Cell Biol.
78:665-670[Medline].
|
| 6.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[CrossRef][Medline].
|
| 7.
|
Cumming, J. N.,
P. Ploypradith, and G. H. Posner.
1997.
Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action.
Adv. Pharmacol.
37:253-297.
|
| 8.
|
Fairfield, A. S.,
S. R. Meshnick, and J. W. Eaton.
1983.
Malaria parasites adopt host cell superoxide dismutase.
Science
221:764-766[Abstract/Free Full Text].
|
| 9.
|
Gachet, Y.,
M. Lee,
B. Sawitzki,
S. Tournier,
T. Poulton, and U. A. Bommer.
1997.
Intracellular colocalisation of the translationally controlled protein P23 with cytoskeletal structures.
Biochem. Soc. Trans.
25:269S[Medline].
|
| 10.
|
MacDonald, S. M.
1996.
Histamine-releasing factors.
Curr. Opin. Immunol.
8:778-783[CrossRef][Medline].
|
| 11.
|
Meshnick, S. R.,
T. E. Taylor, and S. Kamchonwongpaisan.
1996.
Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy.
Microbiol. Rev.
60:301-315[Abstract/Free Full Text].
|
| 12.
|
Peters, W.
1998.
Drug resistance in malaria parasites of animals and man.
Adv. Parasitol.
41:1-62[Medline].
|
| 13.
|
Peters, W., and B. L. Robinson.
1999.
The chemotherapy of rodent malaria. LVI. Studies on the development of resistance to natural and synthetic endoperoxides.
Ann. Trop. Med. Parasitol.
93:325-339[CrossRef][Medline].
|
| 14.
|
Robert, A., and B. Meunier.
1998.
Is alkylation the main mechanism of action of the antimalarial drug artemisinin?
Chem. Soc. Rev.
27:273-279[CrossRef].
|
| 15.
|
Sanchez, J. C.,
D. Schaller,
F. Ravier,
O. Golaz,
S. Jaccoud,
M. Belet,
M. R. Wilkins,
R. James,
J. Deshusses, and D. Hochstrasser.
1997.
Translationally controlled tumor protein: a protein identified in several nontumoral cells including erythrocytes.
Electrophoresis
18:150-155[CrossRef][Medline].
|
| 16.
|
Segovia, M.
1994.
Leishmania gene amplification: a mechanism of drug resistance.
Ann. Trop. Med. Parasitol.
88:123-130[Medline].
|
| 17.
|
Sturzenbaum, S. R.,
P. Kille, and A. J. Morgan.
1998.
Identification of heavy metal induced changes in the expression patterns of the translationally controlled tumour protein (TCTP) in the earthworm Lumbricus rubellus.
Biochim. Biophys. Acta
1398:294-304[Medline].
|
| 18.
|
Wongsrichanalai, C.,
T. D. Nguyen,
N. T. Trieu,
T. Wimonwattrawatee,
P. Sookto,
D. G. Heppner, and F. Kawamoto.
1997.
In vitro susceptibility of Plasmodium falciparum isolates in Vietnam to artemisinin derivatives and other antimalarials.
Acta Trop.
63:151-158[CrossRef][Medline].
|
Antimicrobial Agents and Chemotherapy, February 2000, p. 344-347, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nagamune, K., Moreno, S. N. J., Sibley, L. D.
(2007). Artemisinin-Resistant Mutants of Toxoplasma gondii Have Altered Calcium Homeostasis. Antimicrob. Agents Chemother.
51: 3816-3823
[Abstract]
[Full Text]
-
Afonso, A., Hunt, P., Cheesman, S., Alves, A. C., Cunha, C. V., do Rosario, V., Cravo, P.
(2006). Malaria Parasites Can Develop Stable Resistance to Artemisinin but Lack Mutations in Candidate Genes atp6 (Encoding the Sarcoplasmic and Endoplasmic Reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother.
50: 480-489
[Abstract]
[Full Text]
-
Efferth, T., Sauerbrey, A., Olbrich, A., Gebhart, E., Rauch, P., Weber, H. O., Hengstler, J. G., Halatsch, M.-E., Volm, M., Tew, K. D., Ross, D. D., Funk, J. O.
(2003). Molecular Modes of Action of Artesunate in Tumor Cell Lines. Mol. Pharmacol.
64: 382-394
[Abstract]
[Full Text]
-
ITTARAT, W., PICKARD, A. L., RATTANASINGANCHAN, P., WILAIRATANA, P., LOOAREESUWAN, S., EMERY, K., LOW, J., UDOMSANGPETCH, R., MESHNICK, S. R.
(2003). RECRUDESCENCE IN ARTESUNATE-TREATED PATIENTS WITH FALCIPARUM MALARIA IS DEPENDENT ON PARASITE BURDEN NOT ON PARASITE FACTORS. Am J Trop Med Hyg
68: 147-152
[Abstract]
[Full Text]
-
Bhisutthibhan, J., Meshnick, S. R.
(2001). Immunoprecipitation of [3H]Dihydroartemisinin Translationally Controlled Tumor Protein (TCTP) Adducts from Plasmodium falciparum-Infected Erythrocytes by Using Anti-TCTP Antibodies. Antimicrob. Agents Chemother.
45: 2397-2399
[Abstract]
[Full Text]